Richard D Wasnich

Summary

Affiliation: Radiant Research
Country: USA

Publications

  1. ncbi request reprint Changes in bone density and turnover after alendronate or estrogen withdrawal
    Richard D Wasnich
    Radiant Research Honolulu, Honolulu, HI 96814, USA
    Menopause 11:622-30. 2004
  2. ncbi request reprint Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis
    Michael R McClung
    Oregon Osteoporosis Center, Portland, Oregon 97213, USA
    J Bone Miner Res 19:11-8. 2004
  3. ncbi request reprint Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study
    Michael R McClung
    Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 651, Portland, Oregon 97213, USA
    J Clin Endocrinol Metab 89:4879-85. 2004
  4. ncbi request reprint Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
    Charles H Chesnut
    Osteoporosis Research Group, University of Washington, Seattle, WA, USA
    Curr Med Res Opin 21:391-401. 2005
  5. ncbi request reprint Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents
    Marc C Hochberg
    University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Clin Endocrinol Metab 87:1586-92. 2002
  6. ncbi request reprint Relationship between phalangeal bone density and risk of vertebral fracture
    Misako Ohtsuka
    Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukouka, Japan
    J Clin Densitom 5:11-5. 2002
  7. ncbi request reprint Letter to the editor
    Marc C Hochberg
    Bone 35:1222-4; author reply 1225-6. 2004
  8. ncbi request reprint How useful are measures of BMD and bone turnover?
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, CO, USA
    Curr Med Res Opin 21:545-54. 2005

Detail Information

Publications8

  1. ncbi request reprint Changes in bone density and turnover after alendronate or estrogen withdrawal
    Richard D Wasnich
    Radiant Research Honolulu, Honolulu, HI 96814, USA
    Menopause 11:622-30. 2004
    ..To compare bone mineral density (BMD) and bone turnover changes after therapy withdrawal in postmenopausal women treated with alendronate or estrogen-progestin...
  2. ncbi request reprint Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis
    Michael R McClung
    Oregon Osteoporosis Center, Portland, Oregon 97213, USA
    J Bone Miner Res 19:11-8. 2004
    ..1% and 1.8%, respectively; p < or = 0.0001 versus placebo) with 2.5 mg ibandronate after 24 months. Oral ibandronate is a promising option for the prevention of postmenopausal bone loss...
  3. ncbi request reprint Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study
    Michael R McClung
    Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 651, Portland, Oregon 97213, USA
    J Clin Endocrinol Metab 89:4879-85. 2004
    ..5, 10.3, and 8.9% of women taking placebo, 2.5 mg alendronate, or 5 mg alendronate daily, respectively. Therapy with alendronate is an effective and promising strategy for the prevention of postmenopausal osteoporosis...
  4. ncbi request reprint Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
    Charles H Chesnut
    Osteoporosis Research Group, University of Washington, Seattle, WA, USA
    Curr Med Res Opin 21:391-401. 2005
    ..As osteoporosis medications must be effective across different populations, an additional objective of BONE was to investigate and report the effect of oral ibandronate in North American and European women, as described here...
  5. ncbi request reprint Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents
    Marc C Hochberg
    University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Clin Endocrinol Metab 87:1586-92. 2002
    ..Antiresorptive agents that do not produce large increases in BMD or large reductions in BCM do not appear to and would not be expected to decrease the risk of nonvertebral fractures...
  6. ncbi request reprint Relationship between phalangeal bone density and risk of vertebral fracture
    Misako Ohtsuka
    Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukouka, Japan
    J Clin Densitom 5:11-5. 2002
    ..The phalangeal BMD measurements obtained with this device are not significantly influenced by the presence of osteoarthritis of the hands...
  7. ncbi request reprint Letter to the editor
    Marc C Hochberg
    Bone 35:1222-4; author reply 1225-6. 2004
  8. ncbi request reprint How useful are measures of BMD and bone turnover?
    Paul D Miller
    Colorado Center for Bone Research, Lakewood, CO, USA
    Curr Med Res Opin 21:545-54. 2005
    ..Analyses that have suggested that change in BMD or bone turnover 'explains' little of change in fracture risk with treatment appear to be flawed. Although neither can perfectly predict fracture, they are our current best alternatives...